Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 187-191 , 15 February 2003

Hypoxia-like tissue injury as a component of multiple sclerosis lesions

  • Hans Lassmann

      Affiliations

    • Corresponding Author InformationTel.: +43-1-4277-62811; fax: +43-1-4277-9628.

References 

  1. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 117 cases. Brain. 1999;122:2279–2295
  2. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 2000;47:707–717
  3. Lassmann H. Multiple sclerosis pathology. In:  Compston A editors. McAlpine's multiple sclerosis. 3rd ed.. London: Churchill Livingstone; 1998;p. 323–358
  4. Gay F, Drye T, Dick G, Esiri M. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of primary demyelinating lesion. Brain. 1997;120:1461–1483
  5. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, et al.  Clonal expansion of CD8+ T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 2000;192:393–404
  6. Brueck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, et al.  Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann. Neurol. 1995;38:788–796
  7. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain. 1997;120:393–399
  8. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998;338:278–285
  9. Kornek B, Storch M, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al.  Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive and remyelinated lesions. Am. J. Pathol. 2000;157:267–276
  10. Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann. Neurol. 1981;10:149–158
  11. Storch M, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, et al.  Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998;8:681–694
  12. Genain CP, Cannella B, Hauser SL, Raine CS. Autoantibodies to MOG mediate myelin damage in MS. Nat. Med. 1999;5:170–175
  13. Lucchinetti C, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol. 1996;6:259–274
  14. Chataway J, Sawcer S, Coraddu F, Feakes R, Broadley S, Jones H, et al.  Evidence that allelic variants of the spinocerebellar ataxia type 2 gene influence susceptibility to multiple sclerosis. Neurogenetics. 1999;2:91–96
  15. Fazekas F, Strasser-Fuchs S, Schmidt H, Enzinger C, Ropele S, Lechner A, et al.  Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2000;69:25–28
  16. Hogh O, Oturai A, Schreiber K, Blinkenberg M, Jorgensen O, Ryder L, et al.  Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression. Mult. Scler. 2000;6:226–230
  17. Mojon D, Fujihara K, Hirano M, Miller C, Lincoff N, Jacobs D, et al.  Leber's hereditary optic neuropathy mitochondrial DNA mutations in familial multiple sclerosis. Graefes Arch. Clin. Exp. Ophthalmol. 1999;237:348–350
  18. Giess R, Maurer M, Linker R, Gold R, Warmuth-Metz M, Toyka KV, et al.  Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch. Neurol. 2002;59:407–409
  19. Linker RA, Maurer M, Gaupp S, Martini R, Holtmann B, Giess R, et al.  CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 2002;8:620–624
  20. Itoyama Y, Sternberger N, Webster H, Quarles R, Cohen S, Richardson E. Immunocytochemical observation on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann. Neurol. 1980;7:167–177
  21. Ludwin SK, Johnson ES. Evidence of a “dying-back” gliopathy in demyelinating disease. Ann. Neurol. 1981;9:301–305
  22. Webster HdeF, Shi H, Lassmann H. Immunocytochemical study of myelin associated glycoprotein (MAG), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in chronic relapsing experimental allergic encephalomyelitis (EAE). Acta Neuropathol. (Berl.). 1985;65:177–189
  23. Rodriguez M. Central nervous system demyelination and remyelination in multiple sclerosis and viral models of disease. J. Neuroimmunol. 1992;40:255–263
  24. Itoyama Y, Webster HdeF, Sternberger NH, Richardson EP, Walker DL, Quarles RH, et al.  Distribution of papovavirus, myelin-associated glycoprotein and myelin basic protein in progressive multifocal leukoencephalopathy lesions. Ann. Neurol. 1982;11:396–407
  25. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. J. Clin. Invest. 2000;106:809–812
  26. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Brück W, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol [in press].
  27. Broman T. Blood brain barrier damage in multiple sclerosis. Supra-vital test observations. Acta Neurol. Scand. 1964;10:21–24
  28. Kwon EE, Prineas JW. Blood brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J. Neuropathol. Exp. Neurol. 1994;53:625–636
  29. Kermode AG, Thompson AJ, Tofts B, MacManus DG, Kendall BE, Kingsley DP, et al.  Breakdown of the blood brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain. 1990;113:1477–1489
  30. Prineas JW, McDonald IW. Demyelinating diseases. In:  Graham DI,  Lantos PL editor. Greenfield's neuropathology. 6th ed.. London: Arnold; 1997;p. 813–896
  31. Millan MT, Geczy C, Stuhlmeier KM, Goodman DJ, Ferran C, Bach FH. Human monocytes activate porcine endothelial cells, resulting in increased E-selectin, interleukin-8, monocyte chemotactic protein-1 and plasminogen activator inhibitor-type 1 expression. Transplantation. 1997;63:421–429
  32. Kopp CW, Siegel JB, Hancock WW, Anrather J, Winkler H, Geczy CL, et al.  Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation. 1997;63:749–758
  33. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8 (+) T-cells in a model for multiple sclerosis. J. Exp. Med. 2001;194:669–676
  34. Vass K, Lassmann H. Intrathecal application of interferon gamma progressive appearance of MHC antigens within the rat nervous system. Am. J. Pathol. 1990;137:789–800
  35. Putnam TJ. The pathogenesis of multiple sclerosis: a possible vascular factor. N. Engl. J. Med. 1933;209:786–790
  36. Wakefield A, More L, Difford J, McLaughlin J. Immunohistochemical study of vascular injury in acute multiple sclerosis. J. Clin. Pathol. 1994;47:129–133
  37. Courville CB. Concentric sclerosis. In:  Vinken PJ,  Bruyn GW editor. Handbook of clinical neurology. vol. 9:Amsterdam: Elsevier; 1970;p. 437–451
  38. Lucchinetti CF, Mandler R, McGavern D, Brück W, Gleich G, Ransohoff RM, et al.  A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125:1450–1461
  39. Adams CW. Perivascular iron deposition and other vascular damage in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 1988;51:260–265
  40. Lipton SA. Neuronal injury associated with HIV-1: approaches and treatment. Annu. Rev. Pharmacol. Toxicol. 1998;38:159–177
  41. Werner P, Pitt P, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol. 2001;50:169–180
  42. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 2000;6:62–66
  43. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 2000;6:67–70
  44. De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 1997;56:10–20
  45. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 2001;158:2057–2066
  46. Bitsch A, Wegener C, Da Costa C, Bunkowski S, Reimers CD, Prange HW, et al.  Lesion development in Marburg's type of acute multiple sclerosis: from inflammation to demyelination. Mult. Scler. 1999;5:138–146
  47. Cross AH, Manning PT, Keeling RM, Schmidt RE, Misko TP. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J. Neuroimmunol. 1998;88:45–56
  48. Merrill JE, Ignarro LJ, Sherman MP, Melinek J, Lane TE. Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 1993;151:2132–2141
  49. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain. 1997;120:2149–2157
  50. Smith KJ, Kapoor R, Hall SM, Davies M. Electrically active axons degenerate when exposed to nitric oxide. Ann. Neurol. 2001;49:470–476
  51. Li Z, Chapleau MW, Bates JN, Bielefeldt K, Lee H-C, Abboud FM. Nitric oxide as an autocrine regulator of sodium currents in baroreceptor neurons. Neuron. 1998;20:1039–1049
  52. Mitrovic B, Ignarro LJ, Montestruque S, Smoll A, Merrill JE. Nitric oxide as a potential pathological mechanism in demyelination: its differential effects on primary glial cells in vitro. Neuroscience. 1994;61:575–585
  53. Brorson JR, Schumacker PT, Zhang H. Nitric oxide acutely inhibits neuronal energy production. J. Neurosci. 1999;19:147–158
  54. Beltran B, Mathur A, Duchen MR, Erusalimsky JD, Moncada S. The effect of nitric oxide on cell respiration: a key to understanding its role in cell survival or death. Proc. Natl. Acad. Sci. U. S. A. 2000;97(26):14602–14607
  55. Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D'Acquisto F, et al.  Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor 1 activity by nitric oxide. Blood. 2000;97:9082–9087

PII: S0022-510X(02)00421-5

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 187-191 , 15 February 2003

Article Tools